A166
Phase 3Small molecule
A166 is one of 40 small molecule programs targeting Malignant Tumors. It is currently in Phase 3.
2
Indications
4
Total Trials
3
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1A166
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer2 trials
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06968585·365 enrolled
Malignant Tumors1 trial
A Study of A166 in Patients With Advanced Solid Malignant Tumors
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 1·NCT05311397·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for A166. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details